Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec;40(12):2117-2118.
doi: 10.1007/s00296-020-04715-0. Epub 2020 Oct 12.

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

Chia Siang Kow  1 , Syed Shahzad Hasan  2   3
Affiliations
Comment

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

Chia Siang Kow et al. Rheumatol Int. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Chia Siang Kow and Syed Shahzad Hasan declare that they have no conflict of interest.

Comment on

References

    1. Loarce-Martos J, García-Fernández A, López-Gutiérrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020 doi: 10.1007/s00296-020-04699-x. - DOI - PMC - PubMed
    1. Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J, Yllescas M, Arribas JR; COVID-19@Spain Study Group Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;4:S1198–30431. - PMC - PubMed
    1. Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;1:e13475. - PMC - PubMed
    1. Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, Zink A, Strangfeld A. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(9):1667–1673. doi: 10.1136/annrheumdis-2015-207838. - DOI - PMC - PubMed
    1. van Vollenhoven RF, Emery P, Bingham CO, 3rd, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558–567. doi: 10.3899/jrheum.090856. - DOI - PubMed

LinkOut - more resources